Orphan Drugs

Understanding the Rare Disease Market and its Dynamics

Nonfiction, Health & Well Being, Medical, Ailments & Diseases, Infectious Diseases, General, Medical Science, Pharmacology
Cover of the book Orphan Drugs by Elizabeth Hernberg-Ståhl, Miroslav Reljanović, Elsevier Science
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Elizabeth Hernberg-Ståhl, Miroslav Reljanović ISBN: 9781908818393
Publisher: Elsevier Science Publication: November 15, 2013
Imprint: Woodhead Publishing Language: English
Author: Elizabeth Hernberg-Ståhl, Miroslav Reljanović
ISBN: 9781908818393
Publisher: Elsevier Science
Publication: November 15, 2013
Imprint: Woodhead Publishing
Language: English

This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.

The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.

After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.

The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.

  • A comprehensive overview of strategy, key activities and considerations of how to bring an orphan drug from concept to the market and make it available to patients
  • A source of updated information, news and trends for those who are already active in this fast-evolving field
  • Covers the global definitions and the criteria for getting an orphan drug designation in, for example, the US and Europe
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.

The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.

After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.

The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs.

More books from Elsevier Science

Cover of the book Thermomechanical Behavior of Dissipative Composite Materials by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Pulmonary Endocrine Pathology by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Analysis and Design Principles of MEMS Devices by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book The Physiological and Technical Basis of Electromyography by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Simulation in Textile Technology by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Fundamentals and Applications of Supercritical Carbon Dioxide (SCO2) Based Power Cycles by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Advances in Agronomy by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Chipless RFID Reader Design for Ultra-Wideband Technology by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Advances in Applied Microbiology by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Encyclopedia of Body Image and Human Appearance by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Designing Quiet Structures by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Annual Reports on NMR Spectroscopy by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Surface Modification of Textiles by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Essays on Peripheral Nerve Repair and Regeneration by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
Cover of the book Topics in Behavioral Neurology and Neuropsychology by Elizabeth Hernberg-Ståhl, Miroslav Reljanović
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy